Ocugen to Showcase Modifier Gene Therapy Platform at Key September Conferences
Event summary
- Ocugen will present at three investor and industry conferences in September 2026.
- CEO Dr. Shankar Musunuri will lead fireside chats at Citi and H.C. Wainwright conferences.
- Dr. Raj K. Maturi will present 12-month Phase 2 results for OCU410 gene therapy at The Retina Society meeting.
- Webcasts of Citi and H.C. Wainwright presentations will be available for 30 days post-event.
The big picture
Ocugen's participation in these high-profile conferences underscores the growing interest in modifier gene therapies, which offer a broader approach to treating genetic diseases compared to traditional single-gene therapies. The company's focus on blindness diseases positions it in a niche but rapidly evolving segment of the biotech industry, where competition is intense but the potential market impact is significant.
What we're watching
- Clinical Progress
- The pace at which OCU410 Phase 2 results could accelerate regulatory approval timelines.
- Investor Sentiment
- How investor perception of Ocugen's modifier gene therapy platform evolves post-conference.
- Competitive Positioning
- Whether Ocugen can differentiate itself in the crowded gene therapy space.
Related topics